Core Viewpoint - Hutchison China MediTech Limited (和黄医药) announced the completion of patient enrollment for the SANOVO Phase III study, which evaluates the combination therapy of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for first-line treatment of specific non-small cell lung cancer patients with EGFR mutations and MET overexpression [1] Group 1 - The last patient was enrolled on August 18, 2025, marking the completion of the SANOVO study's patient recruitment [1] - Topline results from the SANOVO study are expected to be announced in the second half of 2026, with plans to submit the findings to relevant academic conferences [1] - If the results are favorable, the company plans to submit a new indication application to the National Medical Products Administration of China [1] Group 2 - ORPATHYS® is a potent and highly selective oral MET tyrosine kinase inhibitor developed in collaboration with AstraZeneca and commercialized by AstraZeneca [1] - TAGRISSO® is an irreversible third-generation EGFR TKI [1]
和黄医药(00013.HK)完成沃瑞沙和泰瑞沙联合疗法的SANOVO中国III期研究患者入组